# US 2009/0270501 A1 · Composition and method for increasing the anabolic state of muscle cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270501 A1
- Document ID: US20090270501A1
- Status: Published application
- Kind: A1
- Application number: 12/499,109
- Filed: 2009-07-08
- Published: 2009-10-29
- Earliest claimed: 2007-09-11
- Inventors: Michele Molino; Joseph MacDougall
- Web page: https://patentgrep.com/patent/US20090270501A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A composition for causing an anabolically-favorable state for muscle in a mammal, comprising ethyl pyruvate and at least one α-hydroxy branched-chain amino acid metabolite.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the α-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.

### Claim 21 (depends on 19)

The composition of claim 19 wherein the ethyl pyruvate and the α-hydroxy branched-chain amino acid metabolite are part of a solid oral dosage form having a multi-phasic rate of dissolution.

### Claim 22 (depends on 21)

The composition of claim 21 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the multi-phasic rate of dissolution provides a time-release mechanism.

### Claim 24 (depends on 22)

The composition of claim 22, further comprising a third-phase, whereby said third-phase has a third rate of dissolution.

### Claim 25 (depends on 23)

The composition of claim 23, wherein the multi-phasic rate of dissolution provides a time-release mechanism.

### Claim 26

A method for causing an anabolically-favorable state of muscle in a mammal, comprising at least the step of administering to the mammal a composition comprising ethyl pyruvate and at least one α-hydroxy branched-chain amino acid metabolite.

### Claim 27 (depends on 26)

The method of claim 26, wherein the .alpha.-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.

### Claim 28 (depends on 26)

The method of claim 26 wherein the ethyl pyruvate and the α-hydroxyisocaproic acid are part of a solid oral dosage form having a multi-phasic rate of dissolution.

### Claim 29 (depends on 28)

The method of claim 28 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.

### Claim 30 (depends on 28)

The method of claim 28, wherein the multi-phasic rate of dissolution provides a time-release mechanism.

### Claim 31 (depends on 29)

The method of claim 29, further comprising a third-phase, whereby said third-phase has a third rate of dissolution.

### Claim 32 (depends on 31)

The method of claim 31, wherein the multi-phasic rate of dissolution provides a time-release mechanism.
